DPP-IV抑制剂列汀类抗糖尿病药物专利分析和专利布局

Analysis for patents of anti-diabetic dipeptidyl peptidase inhibitors

本文采用宏观数据对抗糖尿病药物二肽基肽酶抑制剂列汀类的专利申请进行了分析,对列汀类药物的专利申请态势进行了合理预测;并通过对重点关注的申请人进行剖析,比较了3种不同类型制药企业(美国默沙东、以色列梯瓦、中国恒瑞)在列汀类药物专利布局上的异同,为国内制药企业提供药物专利信息运用和专利布局方面的有益参考和借鉴。

In this paper, we analyzed macroeconomic data about patent applications related to dipeptidyl peptidase （DPP） inhibitors, the anti-diabetic drugs; and predicted the trend of patent applications of DPP reasonably. By analyzing patent applications of three different types of pharmaceutical companies （Merck, Teva, Hengrui） , especially the distribution of patent application period and region, we provided useful information and references on how to utilize and operate pharmaceutical patents to domestic pharmaceutical companies.